European regulators says Lilly Alzheimer’s drug shouldn’t get marketing approval

Please subscribe to IBJ to decode this article.

odpm’tresevld.o .nAtamo rlhredal inoEovil rzen neyrntam tgE iueertubjLo nd li p s eetgysAee.eeakapdeoagen eplcitlr iayc’eU-srfaaiil Ss eiiwetdbsrnstgmru l eslor

ur eafgegd hiegin snte taMei togtos aemshdkzoie oio Euen,nuiashAii mmkird ,d Keuit c snwgn n,dTi rar erse irhodntoeid pbcfwdtnnh rfetaom .ecetue nhcoyiremtafs tti euetln

rerc ot dsu yinehcdldceraMeisto nclpnmoat n noHkia aioae.nteoiao as’PuTmroyif stf fnieoiL e-sUinasmg rflC maix

tat aiea inm ynesyeiKosh oitnpna n hodvuaemmLitanhIanrtdn eeeh xaCnonyclar ah leatio .oelaroyhthsramnachhsnddFeatlssnenpectb ra ,ugsootapiai uthnnJdtge brsiogksrhi we d t tlsi ai dae dghuou tp- de. T i i rrgpukudaira

.tfloCEB Eecl iinhA7lai iasufoersrepiaomr psrrt ,dci molln etgp neaontdom neicie ohzapne’unctu ee a

e bfgh rdtceU ramnaaLdsgpsd v.aoypey.r ud sdsabu-tKdteo,aseEe er .inb efer o arnu armlomssrtsiaavt iihtl fei.rennypomc ,ir id o S,ld eoleJpdets hsimarri eae lmeyiafkeeaJu laaTcmebqrt mu u rrisapaaoaaga fyllga

hcutieiatthrt fbasve ist o.toonmeyntswcr, m pusdehidTtiesga ftnon o a gtrnn e atleha etetoiiai nrlmusdo

imbtememn ulitrsa npt oreg sznta scleirrsahaleuuoic v ouattoitmerme e enri edvsteocr enEm odio aonsthatacd m tlcansrroh. Bt tf ueafet e otuiesmnekoeesiTimeah wtdse.o dieLq ho s sh

tmi. n , rosuieb nh dn oeynkualbbohoert demn tnlri d qrshhtilrtKeue a a-iag ts ptpaie ytqelynirroaesutonmrtbn hgswhdbsieituaietQesmmaopoa soulh hI aa sadtmlmdlyeeheacdo b aiited tLttdlge ireu ncoitnA oz,icwVg.tia’rtbg rBt anihy nu shfbueoe di—oiabnet

93riye h8tnL.o .d miol ccF C$,ah$fyhminrbmr 2le aal2sra.nEdtoSaeoe9 id g n,lio